<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02903576</url>
  </required_header>
  <id_info>
    <org_study_id>12018712.5.0000.5505</org_study_id>
    <nct_id>NCT02903576</nct_id>
  </id_info>
  <brief_title>Stem Cell Therapy for Outer Retinal Degenerations</brief_title>
  <official_title>Stem Cell Derived Retinal Pigmented Epithelium Implantation in Patients With Outer Retinal Degenerations: Phase I/II Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of S達o Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal University of S達o Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase I/II , open label,non randomized, prospective study to determine the
      safety of human embryonic stem cell derived Retinal pigmented epithelium (hESC RPE) sub
      retinal injections versus hESC RPE seeded on a polymeric substrate implanted in the sub
      retinal space,
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine whether the surgical implantation of a human embryonic stem cell-derived retinal
      pigmented epithelium (hESC-RPE) monolayer seeded onto a polymeric versus hESC-RPE injections
      into the sub retinal space is a safe procedure.

      6 Patients will receive hESC-RPE cell injections (100000 cells) in the sub retinal space (2
      Dry Age-related macular degeneration (AMD), 2 Wet AMD with disciform scar and 2 with
      Stargardt's disease).

      Also 5 patients Dry AMD, 5 patients with Wet AMD with disciform scar and 5 patients with
      Stargardt's disease with receive a subretinal implantation of the hESC-RPE seeded in a
      monolayer in a polymeric substrate.

      Patients will be enrolled sequentially, and after the procedure the patients will be followed
      for 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events of sub retinal implantation of stem cell derived retinal pigmented epithelium in the sub retinal space.</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of surgical related side effects: Retinal detachment, Ocular inflammation, Increase in intraocular pressure, Infection( endophthalmitis), Loss of vision due to surgical, related complications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of side effects related to the treatment itself( injection and implantation of sub retinal stem cell related RPE)</measure>
    <time_frame>1 year</time_frame>
    <description>Inflammation/rejection Cell migration/differentiation Tumor formation Proliferative vitreoretinopathy/Retinal detachment Implant migration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <condition>Stargardt's Disease</condition>
  <condition>Exudative Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>injection of hESC-RPE in suspension</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 patients will receive cell suspension injections on the sub retinal space prior to the surgeries, to access safety</description>
  </arm_group>
  <arm_group>
    <arm_group_label>injection hESC-RPE seeded in a substrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15 patients will receive a sub-retinal implantation of a polymeric scaffold seeded hesc- RPE in monolayer</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>injection of hESC-RPE in suspension</intervention_name>
    <description>The first six patients will receive a sub retinal injection of hESC-RPE in solution after a complete pars plana vitrectomy to access safety of the cell implant alone.</description>
    <arm_group_label>injection of hESC-RPE in suspension</arm_group_label>
    <other_name>Human Embryonic Stem Cell - Retinal Pigmented Epithelium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>injection hESC-RPE seeded in a substrate</intervention_name>
    <description>Fifteen patients will receive a sub-retinal implantation of embryonic stem cell derived retinal pigmented epithelium seeded in a polymeric substrate to access safety of substrate seeded with RPE</description>
    <arm_group_label>injection hESC-RPE seeded in a substrate</arm_group_label>
    <other_name>Human Embryonic Stem Cell seeded in a polymeric substrate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with AMD ( Dry , Wet after failure of treatment, disciform scars)

          -  Patients with Stargardt's Disease BCVA on the selected eye: worse than 20/200

        Exclusion Criteria:

          -  Other ophthalmological diseases( Glaucoma, Diabetic Retinopathy, Previous retinal
             surgery, uveitis)

          -  Systemic diseases with contraindication for surgical procedures with local anaesthesia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rubens Belfort, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Federal University of S達o Paulo (UNIFESP)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rodrigo AB Fernandes, MD</last_name>
    <phone>+5511972456473</phone>
    <email>rodrigo.brant@ophthal.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Federal University of Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04023-062</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodrigo AB Fernandes, MD</last_name>
      <phone>+5511972456473</phone>
      <email>rodrigo.brant@ophthal.com.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2016</study_first_submitted>
  <study_first_submitted_qc>September 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2016</study_first_posted>
  <last_update_submitted>August 8, 2017</last_update_submitted>
  <last_update_submitted_qc>August 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of S達o Paulo</investigator_affiliation>
    <investigator_full_name>Rubens Belfort Jr.</investigator_full_name>
    <investigator_title>Full Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
    <mesh_term>Retinal Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>scientific publication in a peer review journal</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

